LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 17

Search options

  1. Article ; Online: Effector-Phase IL-2 Signals Drive Th1 Effector and Memory Responses Dependently and Independently of TCF-1.

    Charley, Krystal R / Ramstead, Andrew G / Matous, Joseph G / Kumaki, Yohichi / Sircy, Linda M / Hale, J Scott / Williams, Matthew A

    Journal of immunology (Baltimore, Md. : 1950)

    2023  Volume 212, Issue 4, Page(s) 586–595

    Abstract: Following viral infection, CD4+ T cell differentiation is tightly regulated by cytokines and TCR signals. Although most activated CD4+ T cells express IL-2Rα after lymphocytic choriomeningtis virus infection, by day 3 postinfection, only half of ... ...

    Abstract Following viral infection, CD4+ T cell differentiation is tightly regulated by cytokines and TCR signals. Although most activated CD4+ T cells express IL-2Rα after lymphocytic choriomeningtis virus infection, by day 3 postinfection, only half of activated T cells maintain expression. IL-2Rα at this time point distinguishes precursors for terminally differentiated Th1 cells (IL-2Rαhi) from precursors for Tfh cells and memory T cells (IL-2Rαlo) and is linked to strong TCR signals. In this study, we test whether TCR-dependent IL-2 links the TCR to CD4+ T cell differentiation. We employ a mixture of anti-IL-2 Abs to neutralize IL-2 throughout the primary CD4+ T cell response to lymphocytic choriomeningitis virus infection in mice or only after the establishment of lineage-committed effector cells (day 3 postinfection). We report that IL-2 signals drive the formation of Th1 precursor cells in the early stages of the immune response and sustain Th1 responses during its later stages (after day 3). Effector-stage IL-2 also shapes the composition and function of resulting CD4+ memory T cells. Although IL-2 has been shown previously to drive Th1 differentiation by reducing the activity of the transcriptional repressor TCF-1, we found that sustained IL-2 signals were still required to drive optimal Th1 differentiation even in the absence of TCF-1. Therefore, we concluded that IL-2 plays a central role throughout the effector phase in regulating the balance between Th1 and Tfh effector and memory cells via mechanisms that are both dependent and independent of its role in modulating TCF-1 activity.
    MeSH term(s) Animals ; Mice ; CD4-Positive T-Lymphocytes ; Cell Differentiation ; Immunologic Memory ; Interleukin-2 ; Interleukin-2 Receptor alpha Subunit ; Mice, Inbred C57BL ; Receptors, Antigen, T-Cell ; Th1 Cells
    Chemical Substances Interleukin-2 ; Interleukin-2 Receptor alpha Subunit ; Receptors, Antigen, T-Cell ; Hnf1a protein, mouse
    Language English
    Publishing date 2023-12-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3056-9
    ISSN 1550-6606 ; 0022-1767 ; 1048-3233 ; 1047-7381
    ISSN (online) 1550-6606
    ISSN 0022-1767 ; 1048-3233 ; 1047-7381
    DOI 10.4049/jimmunol.2300570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol

    Kumaki, Yohichi / Salazar, Andres M / Wandersee, Miles K / Barnard, Dale L

    Antiviral research

    2016  Volume 139, Page(s) 1–12

    Abstract: ... ...

    Abstract Hiltonol
    MeSH term(s) Adjuvants, Immunologic ; Administration, Intranasal ; Animals ; Carboxymethylcellulose Sodium/administration & dosage ; Carboxymethylcellulose Sodium/analogs & derivatives ; Carboxymethylcellulose Sodium/therapeutic use ; Disease Models, Animal ; Immunomodulation ; Interferon Inducers/administration & dosage ; Interferon Inducers/therapeutic use ; Lung/drug effects ; Lung/pathology ; Lung/virology ; Mice ; Mice, Inbred BALB C ; Poly I-C/administration & dosage ; Poly I-C/therapeutic use ; Polylysine/administration & dosage ; Polylysine/analogs & derivatives ; Polylysine/therapeutic use ; SARS Virus/drug effects ; Severe Acute Respiratory Syndrome/drug therapy ; Severe Acute Respiratory Syndrome/mortality ; Severe Acute Respiratory Syndrome/prevention & control ; Severe Acute Respiratory Syndrome/virology ; Survival Analysis
    Chemical Substances Adjuvants, Immunologic ; Interferon Inducers ; Polylysine (25104-18-1) ; poly ICLC (7KYP9TKT70) ; Carboxymethylcellulose Sodium (K679OBS311) ; Poly I-C (O84C90HH2L)
    Keywords covid19
    Language English
    Publishing date 2016-12-09
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2016.12.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

    Barnard, Dale L / Kumaki, Yohichi

    Future virology

    2011  Volume 6, Issue 5, Page(s) 615–631

    Abstract: Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in early 2003 to cause a very severe acute respiratory syndrome, which eventually resulted in a 10% case-fatality rate. Owing to excellent public health measures that isolated focus cases ... ...

    Abstract Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in early 2003 to cause a very severe acute respiratory syndrome, which eventually resulted in a 10% case-fatality rate. Owing to excellent public health measures that isolated focus cases and their contacts, and the use of supportive therapies, the epidemic was suppressed to the point that further cases have not appeared since 2005. However, despite intensive research since then (over 3500 publications), it remains an untreatable disease. The potential for re-emergence of the SARS-CoV or a similar virus with unknown but potentially serious consequences remains high. This is due in part to the extreme genetic variability of RNA viruses such as the coronaviruses, the many animal reservoirs that seem to be able host the SARS-CoV in which reassortment or recombination events could occur and the ability coronaviruses have to transmit relatively rapidly from species to species in a short period of time. Thus, it seems prudent to continue to explore and develop antiviral chemotherapies to treat SARS-CoV infections. To this end, the various efficacious anti-SARS-CoV therapies recently published from 2007 to 2010 are reviewed in this article. In addition, compounds that have been tested in various animal models and were found to reduce virus lung titers and/or were protective against death in lethal models of disease, or otherwise have been shown to ameliorate the effects of viral infection, are also reported.
    Keywords covid19
    Language English
    Publishing date 2011-04-27
    Publishing country England
    Document type Journal Article
    ISSN 1746-0794
    ISSN 1746-0794
    DOI 10.2217/fvl.11.33
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice.

    Kumaki, Yohichi / Morrey, John D / Barnard, Dale L

    Future virology

    2012  Volume 7, Issue 8, Page(s) 801–818

    Abstract: Statins are used to control elevated cholesterol or hypercholesterolemia, but have previously been reported to have antiviral properties. AIMS: To show efficacy of statins in various influenza virus mouse models. MATERIALS & METHODS: BALB/c mice were ... ...

    Abstract Statins are used to control elevated cholesterol or hypercholesterolemia, but have previously been reported to have antiviral properties. AIMS: To show efficacy of statins in various influenza virus mouse models. MATERIALS & METHODS: BALB/c mice were treated intraperitoneally or orally with several types of statins (simvastatin, lovastatin, mevastatin, pitavastatin, atorvastatin or rosuvastatin) at various concentrations before or after infection with either influenza A/Duck/ MN/1525/81 H5N1 virus, influenza A/Vietnam/1203/2004 H5N1 virus, influenza A/ Victoria/3/75 H3N2 virus, influenza A/NWS/33 H1N1 virus or influenza A/CA/04/09 H1N1pdm09 virus. RESULTS: The statins administered intraperitoneally or orally at any dose did not significantly enhance the total survivors relative to untreated controls. In addition, infected mice receiving any concentration of statin were not protected against weight loss due to the infection. None of the statins significantly increased the mean day of death relative to mice in the placebo treatment group. Furthermore, the statins had relatively few ameliorative effects on lung pathology or lung weights at day 3 and 6 after virus exposure, although mice treated with simvastatin did have improved lung function as measured by arterial saturated oxygen levels in one experiment. CONCLUSION: Statins showed relatively little efficacy in any mouse model used by any parameter tested.
    Language English
    Publishing date 2012-06-16
    Publishing country England
    Document type Journal Article
    ISSN 1746-0794
    ISSN 1746-0794
    DOI 10.2217/fvl.12.71
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.

    Cao, Rui-Yuan / Xiao, Jun-Hai / Cao, Bin / Li, Song / Kumaki, Yohichi / Zhong, Wu

    Antiviral chemistry & chemotherapy

    2014  Volume 23, Issue 6, Page(s) 237–240

    Abstract: Background: A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 ... ...

    Abstract Background: A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.
    Methods: In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and rimantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.
    Results: All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.
    Conclusions: Our data show a pattern of antiviral sensitivity for this novel H7N9 strain of influenza that suggests the compounds oseltamivir, peramivir and favipiravir should be useful for therapy.
    MeSH term(s) Amides/pharmacology ; Animals ; Antiviral Agents/pharmacology ; Cyclopentanes/pharmacology ; Dogs ; Drug Resistance, Viral/drug effects ; Guanidines/pharmacology ; Influenza A Virus, H7N9 Subtype/drug effects ; Madin Darby Canine Kidney Cells ; Oseltamivir/pharmacology ; Pyrazines/pharmacology ; Reassortant Viruses/drug effects
    Chemical Substances Amides ; Antiviral Agents ; Cyclopentanes ; Guanidines ; Pyrazines ; Oseltamivir (20O93L6F9H) ; favipiravir (EW5GL2X7E0) ; peramivir (QW7Y7ZR15U)
    Language English
    Publishing date 2014-12-16
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1033586-9
    ISSN 2040-2066 ; 0956-3202
    ISSN (online) 2040-2066
    ISSN 0956-3202
    DOI 10.3851/IMP2672
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro.

    Kumaki, Yohichi / Woolcott, John D / Roth, Jason P / Mclean, Tyler Z / Smee, Donald F / Barnard, Dale L / Valiaeva, Nadejda / Beadle, James R / Hostetler, Karl Y

    Antiviral research

    2018  Volume 158, Page(s) 122–126

    Abstract: On September 22, 2008, a physician on Prince of Wales Island, Alaska, notified the Alaska Department of Health and Social Services (ADHSS) of an unusually high number of adult patients with recently diagnosed pneumonia (n = 10), including three persons ... ...

    Abstract On September 22, 2008, a physician on Prince of Wales Island, Alaska, notified the Alaska Department of Health and Social Services (ADHSS) of an unusually high number of adult patients with recently diagnosed pneumonia (n = 10), including three persons who required hospitalization and one who died. ADHSS and CDC conducted an investigation to determine the cause and distribution of the outbreak, identify risk factors for hospitalization, and implement control measures. This report summarizes the results of that investigation, which found that the outbreak was caused by adenovirus 14 (Ad14), an emerging adenovirus serotype in the United States that is associated with a higher rate of severe illness compared with other adenoviruses. Among the 46 cases identified in the outbreak from September 1 through October 27, 2008, the most frequently observed characteristics included the following: male (70%), Alaska Native (61%), underlying pulmonary disease (44%), aged > or = 65 years (26%), and current smoker (48%). Patients aged > or = 65 years had a fivefold increased risk for hospitalization. The most commonly reported symptoms were cough (100%), shortness of breath (87%), and fever (74%). Of the 11 hospitalized patients, three required intensive care, and one required mechanical ventilation. One death was reported. Ad14 isolates obtained during the outbreak were identical genetically to those in recent community-acquired outbreaks in the United States which suggests the emergence of a new, and possibly more virulent Ad14 variant. Clinicians should consider Ad14 infection in the differential diagnosis for patients with community-acquired pneumonia, particularly when unexplained clusters of severe respiratory infections are detected.
    MeSH term(s) A549 Cells ; Adenovirus Infections, Human/epidemiology ; Adenovirus Infections, Human/virology ; Adenoviruses, Human/drug effects ; Adenoviruses, Human/pathogenicity ; Aged ; Disease Outbreaks ; Esters/pharmacology ; Female ; Fever ; Humans ; Male ; Nucleosides/analogs & derivatives ; Nucleosides/pharmacology ; Regression Analysis ; Respiratory Tract Infections/virology ; Serogroup ; United States
    Chemical Substances Esters ; Nucleosides
    Language English
    Publishing date 2018-08-07
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2018.08.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.

    Scharton, Dionna / Bailey, Kevin W / Vest, Zachary / Westover, Jonna B / Kumaki, Yohichi / Van Wettere, Arnaud / Furuta, Yousuke / Gowen, Brian B

    Antiviral research

    2014  Volume 104, Page(s) 84–92

    Abstract: Rift Valley fever is a zoonotic, arthropod-borne disease that affects livestock and humans. The etiologic agent, Rift Valley fever virus (RVFV; Bunyaviridae, Phlebovirus) is primarily transmitted through mosquito bites, but can also be transmitted by ... ...

    Abstract Rift Valley fever is a zoonotic, arthropod-borne disease that affects livestock and humans. The etiologic agent, Rift Valley fever virus (RVFV; Bunyaviridae, Phlebovirus) is primarily transmitted through mosquito bites, but can also be transmitted by exposure to infectious aerosols. There are presently no licensed vaccines or therapeutics to prevent or treat severe RVFV infection in humans. We have previously reported on the activity of favipiravir (T-705) against the MP-12 vaccine strain of RVFV and other bunyaviruses in cell culture. In addition, efficacy has also been documented in mouse and hamster models of infection with the related Punta Toro virus. Here, hamsters challenged with the highly pathogenic ZH501 strain of RVFV were used to evaluate the activity of favipiravir against lethal infection. Subcutaneous RVFV challenge resulted in substantial serum and tissue viral loads and caused severe disease and mortality within 2-3 days of infection. Oral favipiravir (200 mg/kg/day) prevented mortality in 60% or greater of hamsters challenged with RVFV when administered within 1 or 6h post-exposure and reduced RVFV titers in serum and tissues relative to the time of treatment initiation. In contrast, although ribavirin (75 mg/kg/day) was effective at protecting animals from the peracute RVFV disease, most ultimately succumbed from a delayed-onset neurologic disease associated with high RVFV burden observed in the brain in moribund animals. When combined, T-705 and ribavirin treatment started 24 h post-infection significantly improved survival outcome and reduced serum and tissue virus titers compared to monotherapy. Our findings demonstrate significant post-RVFV exposure efficacy with favipiravir against both peracute disease and delayed-onset neuroinvasion, and suggest added benefit when combined with ribavirin.
    MeSH term(s) Amides/pharmacology ; Amides/therapeutic use ; Animals ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Cell Line ; Central Nervous System Viral Diseases/drug therapy ; Central Nervous System Viral Diseases/mortality ; Central Nervous System Viral Diseases/pathology ; Central Nervous System Viral Diseases/virology ; Cricetinae ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Female ; Microbial Sensitivity Tests ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; Rift Valley Fever/drug therapy ; Rift Valley Fever/mortality ; Rift Valley Fever/pathology ; Rift Valley Fever/virology ; Rift Valley fever virus/drug effects ; Rift Valley fever virus/enzymology ; Viral Load
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; favipiravir (EW5GL2X7E0)
    Keywords covid19
    Language English
    Publishing date 2014-01-31
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2014.01.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

    Kumaki, Yohichi / Day, Craig W / Smee, Donald F / Morrey, John D / Barnard, Dale L

    Antiviral research

    2011  Volume 92, Issue 2, Page(s) 329–340

    Abstract: Various fluorodeoxyribonucleosides were evaluated for their antiviral activities against influenza virus infections in vitro and in vivo. Among the most potent inhibitors was 2'-deoxy-2'-fluorocytidine (2'-FdC). It inhibited various strains of low and ... ...

    Abstract Various fluorodeoxyribonucleosides were evaluated for their antiviral activities against influenza virus infections in vitro and in vivo. Among the most potent inhibitors was 2'-deoxy-2'-fluorocytidine (2'-FdC). It inhibited various strains of low and highly pathogenic avian influenza H5N1 viruses, pandemic H1N1 viruses, an oseltamivir-resistant pandemic H1N1 virus, and seasonal influenza viruses (H3N2, H1N1, influenza B) in MDCK cells, with the 90% inhibitory concentrations ranging from 0.13 to 4.6 μM, as determined by a virus yield reduction assay. 2'-FdC was then tested for efficacy in BALB/c mice infected with a lethal dose of highly pathogenic influenza A/Vietnam/1203/2004 H5N1 virus. 2'FdC (60 mg/kg/d) administered intraperitoneally (i.p.) twice a day beginning 24 h after virus exposure significantly promoted survival (80% survival) of infected mice (p=0.0001). Equally efficacious were the treatment regimens in which mice were treated with 2'-FdC at 30 or 60 mg/kg/day (bid X 8) beginning 24 h before virus exposure. At these doses, 70-80% of the mice were protected from death due to virus infection (p=0.0005, p=0.0001; respectively). The lungs harvested from treated mice at day four of the infection displayed little surface pathology or histopathology, lung weights were lower, and the 60 mg/kg dose reduced lung virus titers, although not significantly compared to the placebo controls. All doses were well tolerated in uninfected mice. 2'-FdC could also be administered as late as 72 h post virus exposure and still significantly protect 60% mice from the lethal effects of the H5N1 virus infection (p=0.019). Other fluorodeoxyribonucleosides tested in the H5N1 mouse model, 2'-deoxy-5-fluorocytidine and 2'-deoxy-2',2'-difluorocytidine, were very toxic at higher doses and not inhibitory at lower doses. Finally, 2'-FdC, which was active in the H5N1 mouse model, was also active in a pandemic H1N1 influenza A infection model in mice. When given at 30 mg/kg/d (bid X 5) beginning 24h before virus exposure), 2'-FdC also significantly enhanced survival of H1N1-infected mice (50%, p=0.038) similar to the results obtained in the H5N1 infection model using a similar dosing regimen (50%, p<0.05). Given the demonstrated in vitro and in vivo inhibition of avian influenza virus replication, 2'FdC may qualify as a lead compound for the development of agents treating influenza virus infections.
    MeSH term(s) Animals ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacology ; Cell Line ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Dogs ; Female ; Histocytochemistry ; Influenza A Virus, H1N1 Subtype/drug effects ; Influenza A Virus, H3N2 Subtype/drug effects ; Influenza A Virus, H5N1 Subtype/drug effects ; Injections, Intraperitoneal ; Lung/pathology ; Lung/virology ; Mice ; Mice, Inbred BALB C ; Microbial Sensitivity Tests ; Orthomyxoviridae Infections/drug therapy ; Orthomyxoviridae Infections/prevention & control ; Orthomyxoviridae Infections/virology ; Survival Analysis ; Viral Load
    Chemical Substances Antiviral Agents ; Deoxycytidine (0W860991D6) ; 2'-fluoro-2'-deoxycytidine (LCY080JPY9)
    Keywords covid19
    Language English
    Publishing date 2011-09-08
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2011.09.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Evaluation of Interferon Inducers, Ribavirin and Mouse Hyperimmune Serum in a Pathogenesis/Lethal Mouse Model Using a Mouse-adapted SARS-CoV

    Barnard, Dale / Day, Craig / Wandersee, Miles / Kumaki, Yohichi / Salazar, Andres

    Antiviral Res

    Keywords covid19
    Publisher PMC
    Document type Article ; Online
    DOI 10.1016/j.antiviral.2008.01.025
    Database COVID19

    Kategorien

  10. Article ; Online: Prophylactic Efficacy of Intranasally Administered HSP Nanoparticles for Treating a Lethal SARS-CoV Infection in BALB/c Mice

    Barnard, Dale / Wiley, James / Wandersee, Miles / Kumaki, Yohichi / Young, Mark / Douglas, Trevor / Harmsen, Allan

    Antiviral Res

    Keywords covid19
    Publisher PMC
    Document type Article ; Online
    DOI 10.1016/j.antiviral.2009.02.059
    Database COVID19

    Kategorien

To top